Epidemiology and histopathology of breast cancer in iran versus other middle eastern countries by Nafissi, N. et al.
Original Article
Middle East Journal of Cancer; July 2015 6(3): 
♦Corresponding Author: 
Epidemiology and Histopathology of
Breast Cancer in Iran versus Other Middle
Eastern Countries
Nahid Nafissi*, Maryam Khayamzadeh**, Zahra Zeinali***, 
Davood Pazooki*, Mostafa Hosseini*, Mohammad Esmaeil Akbari**♦
*Breast Surgery Department, Iran University of Medical Sciences, Tehran, Iran
**Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
***Medical Student, International Federation of Medical Students' Associations, Tehran, Iran
Mideast East Special Report
8; 9(3): 243-251
♦Corresponding Author: 
Mohammad Esmaeil Akbari,
MD
Cancer Research Center,
Shohada-e-Tajrish Hospital,
Tajrish Square, Tehran, Iran
Tel: +98-2122748001
Email:drakbari.drakbari@gmail.com
khayamzadeh@yahoo.com
Abstract
Background: Breast cancer is the most prevalent cancer among females worldwide.
This study compares the results of the most cited published Iranian studies and studies
from other Middle East countries on breast cancer with data from the Ministry of Health
and Medical Education and approximately 2000 cases from the Cancer Research
Center of Shahid Beheshti Medical University of Iran.
Methods: Data from the Cancer Registry System of the Ministry of Health and
Medical Education and the Cancer Research Center were obtained in addition to data
from other published Iranian articles to increase the accuracy of incidence, prevalence,
disease burden, risk factors, clinical staging, clinical pathology, biological markers,
clinical subtypes, and survival rate of breast cancer in the last decade and compare the
epidemiological data with other areas of the world.
Results: Overall, breast cancer was the most common cancer in Iran. The age-
standardized rate for breast cancer was 33.21 per 100,000 according to the latest
national databases. The mortality rate for breast cancer has not changed in the past 30
years in Iran. The age-standardized rate for mortality was 14.2 per 100,000 with a mean
age of 49.84 years. The most common cancer in Iran is invasive ductal carcinoma. In
our last review, 65.5%-70.5% of cases were in the early stages (1 and 2) and less than
30% were in the advanced stages. The five-year overall survival rate was estimated at
72% in women and 60% in men. The stage and number of positive lymph nodes
significantly affected the survival rate.
In the Gulf Cooperation Council, ASR of the Kingdom of Saudi Arabia was (12.9),
Bahrain (46.4), Kuwait (44.3), Qatar (35.5), United Arab Emirates (19.2), and Oman
(14.4) per 100,000. 
Conclusion: Our study shows that epidemiology and histopathology of cancer is
different with other neighborhood countries and is multi-dimension and needs multi-
center involvement from government authorities, clinicians and scientists.
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Introduction
According to GLOBOCAN report,
approximately 1.38 million new Breast cancer
cases have been diagnosed in 2008 and 1.67
million in 2012.1 Therefore, breast cancer
comprises 23% of all female cancers.2 The most
common cancers in females are breast or cervical
cancer worldwide, with the exception of China
(lungs), South Korea (thyroid), Mongolia and
Vietnam (liver).3
Female breast cancer incidence rates varied
internationally by more than 13-fold in 2008
between different countries and ranged from 8.0
cases per 100,000 in Mongolia and Bhutan to
109.4 per 100,000 in Belgium. North America
and Northern Europe had the highest age-
standardized rates (ASR), whereas the lowest
rates were in Asia and Africa.3,4 Worldwide, the
incidence of breast cancer increased by 3.1%
annually between 1980 and 2010.5
An estimated 1 in 8 women in the United
States will develop this disease. The rate is very
high in Eastern (93.1 per 100,000) and Western
(89.7 per 100,000) Europe according to a
GLOBOCAN report (Table 1).2
In the Gulf Cooperation Council, the Kingdom
of Saudi Arabia had the lowest ASR (12.9),
whereas Bahrain had the highest (46.4) followed
by Kuwait (44.3), Qatar (35.5), United Arab
Emirates (19.2), and Oman (14.4)per 100,000.6
Age standardized rate (ASR) for breast cancer
incidence in 2012 was 33.21 (Iran national
database), 28.1 (Iran, Globocan), 41.9 (Eastern
Mediterranean Region), 82.1(European Union),
85.8 (Australia and New Zealand), 79.8 (Canada)
and 92.9 (USA).
The incidence of breast cancer by age and
geographic distribution shows that in developing
countries this incidence is 23% in young adults
(15-49 years) versus 10% in developed countries.
In menopausal females ( >50 years) the incidence
is 28% in developing countries versus 39% in
developed countries.7 Hence, menopausal females
from developed countries have a greater incidence
of cancer.
According to the 2014 GLOBOCAN database,
there was no significant difference in the
incidence, mortality, and prevalence of breast
cancer in Iran compared to the worldwide database
(Table1).1
According to the developing countries
databases, the cumulative probability for breast
cancer incidence in individuals aged 15-79 years
in Iran increased during the previous 30 years as
follows: 1.4 (0.9-2.9) in 1980; 1.8 (1.1-2.8) in
1990; 2.1 (1.9-2.4) in 2000; and 2.2 (1.8-2.7) in
2010.7 Figure 1 shows the increased incidence rate
of breast cancer from 2005-2008 in Iran.
Based on the Iranian Cancer Registry Report
in 2009, there were 8616 women diagnosed with
breast cancer with an ASR of 28.1 per 100,000
females.8 Table 2 shows the ASR of breast cancer
in Iran (2005-2006) according to the National
Cancer Registry system.
The prevalence of breast cancer has shown an
annual 3.1% increase worldwide from 1980 to
2010.5 The five-year prevalence of breast cancer
showed that the estimated number and proportion
Figure 1.Trend in age-specific rate (ASR) for breast cancer from
2005 to 2009 in Iran.
Figure 2. Trend of breastfeeding in case and control groups in Iran.12
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of people with breast cancer during the previous
5 years was 6,255,391 worldwide and 34175 in
Iran.1 According to result of unpublished research
from Cancer Research Center, Shahid Beheshti
University of Medical Sciences, the five-year
prevalence of breast cancer was 28750 in 2006.
Akbari et al. reported that the mean age for
breast cancer in Iran was 5 years earlier in Iranian
women compared to women from developed
countries (Table 3). According to the national
cancer registry database, 57.6% of breast cancer
cases were seen in women <50 years of age.10, 11
Breast cancer is the second leading cause of
cancer deaths (15.4%) in developed countries
after lung cancer. In Iran, it is the fifth leading
cause of cancer deaths like other parts of the
world and it is estimated 14.2% of death.1,11,12
The global total number of deaths from breast
cancer has increased from 250000 (95% CI:
239000-296000) in 1980 to 425000 (359000-
453000) in 2010, at an annual increase of 1.8%.7
From 1980 to 2010, deaths among reproductive-
aged women from breast cancer increased 1.8%
per year. The proportion of breast and cervical
cancer deaths in women younger than 50 years
varied from 0.13 in central Europe to 0.37 in the
Middle East.7 Table 4 shows the cumulative
probability for breast cancer deaths among
individuals aged 15-79 years in the last 30 years
in Iran.7
The age standardized mortality rate (ASR) did
not substantially change during the past 30 years;
this rate in Iran (14.2) was similar to developed
countries such as USA (14.9), Canada (13.9),
Australia and New Zealand (14.5), Turkey had a
mortality rate of 11.9 per 100,00013 whereas the
mortality rate in India was 12.7 per 100,00014
The ASR of IRAN is less than other countries in
our region Eastern Mediterranean region (EMRO)
(8.6).1
Materials and Methods
Numerous published data exist that pertain to
breast cancer status in Iran in the Cancer Research
Center (CRC), Shahid Beheshti Medical
University. These data cover epidemiological,
clinical, pathological, radiological, economical,
geographical distribution, ethnicity, efficacy and
benefit of diagnostic and therapeutic intervention
for breast cancer. In the current study, we have
collected and organized these data to determine the
actual status of breast cancer in Iran. The main data
Figure 3. Trend for clinical stage of diagnosed breast cancer in Iran (1985-2013).
Table 1. Difference in incidence, mortality and five-year prevalence between the worldwide database and Iran (2014).1
Breast Number Incidence (%) ASR(W) Number Mortality (%) ASR (W) Number 5-year
cancer prevalence (%)
World 1,676,633 25.2 43.3 521,817 14.7 12.9 6,255,391 36.4
Iran 9795 24.5 28.1 3304 14.2 9.9 34105 37.7
ASR: Age-standardized rate (W): World Standard Population
Frequency
Stage of Tumor
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source was obtained from the Cancer Registry
Department of the Health Ministry, data extracted
from published articles, and data provided by the
CRC at SBMU. There were some published data
from other institutes in Iran, which were not
compared and compiled with our data. We
attempted to compare the status of breast cancer
in Iran with other areas of the world according to
international data from International Agency for
Research on Cancer (IARC), GLOBOCAN, and
specially with published articles from Middle
East countries and other sources for comparison.
Results
Age and gender
In Iran, the mean age at breast cancer diagnosis
according to various published articles was 47.95-
54.6 years. According to the national database
the mean age was 49.84 years and half of the
patients (median) were ≤48 years of age.11 In a
research, the median age of breast cancer in Iran
was reported 49 years.15 The most common patient
age group was 41-49 years (34.5%),9-12,16-19
however another study reported 45-54 years of
age.20
The rate of breast cancer in men was 2.8%,
which was much higher than other parts of the
world.11
Risk and protective factors
WHO reported that breastfeeding, higher
physical activity, and healthy weight are associated
with a lower risk of breast cancer.3
Protective factors included young age at first
full-term pregnancy and multiparity are
highlighted in breast cancer. 1-3 parities are the
most protective effects.12,18,21,22
The role of long-term breast feeding of 18-24
months per child had significant protective
effects.12 In one study by Akbari et al., it was
shown that 70% of breast cancer cases and 86%
of controls had histories of breast feeding, whereas
29.5% of breast cancer cases and 14% of controls
had no history of breastfeeding. This study showed
that fewer patients fed the kids and other patients
Table 2. Age-specific rate (ASR) for the incidence of breast
cancer in Iran from 2005-2006 (n = 5981).9
Age groups (years) Incidence rate
15-19 0.02
20-14 0.78
25-29 5.91
30-34 14.74
35-39 33.14
40-44 47.90
45-49 74.03
50-54 74.31
55-59 69.28
60-64 69.09
65-69 48.58
70-74 43.71
75-79 4453
80-84 58-45
≥ 85 22.09
Crudo rate 17.44
Age specific rate (weighted) 23.06
Figure 4. Disease-free survival (DFS) in patients with breast
cancer recurrence in Iran. Variables significantly influenced DFS
according to univariate analysis.
Figure 5. Overall survival for breast cancer patients (national
data).11
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had less time breast feeding. (Figure 2).12,22
However, tobacco consumption and overweight
increased the risk for breast cancer (P=0.02 and
0.04, respectively). Increased body mass index
(BMI), as a risk factor, was calculated in one
study. The results showed that mean BMI (SD) in
cases [27.9 (3.9)] compared to the controls [26.3
(4.3)] significantly differed (P=0.004).23
In a published study, oral contraceptive
(estrogen, progesterone) is not a risk factor for
breast cancer.12,21-23
A significant difference existed between cases
that had a positive family history for breast cancer
(22.8%) compared to 16.9% for controls.12,21,22
Pathology
Statistical analysis of 5 studies showed that
invasive ductal carcinoma (89.5%-93%) was the
most frequent cancer followed by invasive lobular
carcinoma (2.8%-5.9%). The frequency of in-situ
carcinoma was 1.2%-3.2%; other types were
<7%.11,16,18,22,24 The data Analysis of data pooled
from 2224 cases at the Cancer Research Center
showed a little difference in frequency of different
types of breast cancer (Table 5).
Clinical staging
From 2006-2011, there were a number of
Iranian studies conducted on breast cancers. These
studies included more than 1606 patients - 65.5%
diagnosed with early stage breast cancer and
34.5% with advanced stage cancer.25,26 However,
data from the CRC for 2007-2013 of 1812 cases
(unpublished data) showed that 70.5% of patients
had early stage breast cancer and 29.5% had
advanced stage cancer.
A comparison of the 2001-2005 report with the
65% early stage cancer finding showed a slight
change to 2006-2011 (67.62%). Improvements
in medical practice and earlier diagnosis in the past
decade is responsible for this down
staging.8,10,17,24-27
Stage of tumor
Between 1985-1995 (P=0.24) and 2007-2013
(P=0.1), there was no significant difference in
the stages 0 and 1 disease; however there were
significant difference in patients with stages 2
and 3 during the mentioned years (P<0.001;
P<0.001). It means the patients were diagnosed in
earlier stages in recent years (2007-2013) (Table
6, Figure 3).
Biologic markers
Biological biomarkers like tumor size, grade,
histologic feature, and lymph node status, can
provide information on disease prognosis and
outcome. According to studies in the last 12 years,
estrogen receptor (ER), progesterone receptor
(PR), and P53 were available, and the C-erb
oncogene was available only for 7 years. Only ER
was related to age, which meant that older patients
had increased ER positivity, which possibly
explain the better prognosis with increased age.
26,28,29
Table 7 shows the range of positive receptors
in five different studies. A tremendous difference
in reported HER2 (14%-71%) existed, which
appeared to be from differences in how HER2 was
measured and the test quality.
A national policy should be designed to
Table 4. The cumulative probability for death attributed to breast
cancer death in Iran.
Year Death Rate 95% Confidence
Interval (CI)
1980 0.6 0.3-1.1
1990 0.7 0.4-1.1
2000 0.7 0.7-0.8
2010 0.7 0.5-0.8
Table 3. Age distribution of breast cancer patients according to
age (years) in Iran. 
Age (years) Number Percent
<30 39 6.4
30-34 42 6.9
35-39 89 14.5
40-44 114 18.6
45-49 125 20.4
50-54 83 13.5
55-59 59 9.6
60-64 23 3.8
65-69 22 3.6
70-74 17 2.8
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standardize laboratories that evaluate HER2
receptor in order to unify the results obtained in
future studies.
Recurrence and survival
In early stage breast cancer, all cases who were
less than 70 years of age with a tumor size greater
than one cm or lymph node positive undergo
adjuvant chemotherapy. All hormone receptor
positive patients received hormone therapy. In
terms of surgical type, all lymph node positive
patients and those who undergo breast conserving
surgery received radiotherapy.
A study of overall survival, disease-free
survival (DFS), and recurrence has reported that
only two factors correlated with recurrence:
absence of two steroid receptors and
lymphovascular invasion (LVI).30 Although early
detection with no lymph node involvement and
small tumor size are important in patients with
breast cancer, the type of bio-marker involved
should also be considered when survival is
investigated.
According to a new published study from the
CRC database, age lower than 40, higher stage at
time of diagnosis, higher grade of tumor, large
tumor size and negative ER and PR are important
factors in early and late recurrence.31 The median
interval for recurrence or DFS was 3.6 years
(range: 0-24.18 years). Disease-free survival was
96% at one year and 80% 5-years after diagnosis
(Figure 4). Relapse was observed in 54% of cases
1-5 years after treatment.31
The 5-year overall survival rate was not related
to the type of surgery,10, 30 and estimated 72% in
women and 60% in men. Hence, the survival
rates for men were less than the global overall
survival rate.11
Overall survival significantly differs by stages
and number of positive lymph nodes. The five-
year survival rates of 81%-88% and ten-year
survival rates of 77%-81% have been reported.10
A national Iranian study conducted in 2010
on over 6147 patients reported a five-year survival
rate of 71% (Figure 5).11
When survival was computed according to
cancer subtypes, a new finding was established.
In the four breast cancer subtypes, the luminal
A subtype (ER+ or PR+ and HER2-) was the
most common, whereas the HER2 enriched
subtype (ER-, PR- and HER2+) was the least
common with the highest and the lowest five-
year survival probabilities.32
Discussion 
Breast cancer, with an ASR of 33.2 per 100,000
is the most common cancer in Iranian females. The
lowest is 8.0 cases per 100,000 in Mongolia and
highest at 109.4 per 100,000 in Belgium. Yearly,
the ASR has increased by 1.5 per 100,000.33
Pakistan has the second highest ASR in the
Middle East with 50.3 per 100,000.34,35 In the
Gulf Cooperation Council, the Kingdom of Saudi
Arabia had the lowest ASR (12.9), whereas
Bahrain had the highest (46.4) followed by Kuwait
(44.3), Qatar (35.5), United Arab Emirates (19.2),
and Oman (14.4) per 100,000.6 Western Turkey
had an ASR of 50 per 100,000 compared to
Eastern Turkey with 20 per 100,000. This
difference was due to the Western life style.36
The average ASR was 25.8 per 100,000 in
different states of the India.14
This study intended to find the differences in
statistical results of Iranian studies and the CRC-
SBMU_database of approximately1700 new
cases. The mean age of different Iranian studies
was 47-50 years. The mean age in Pakistan was
48.6 years34,35 48 years in Saudi Arabia.6
The most common pathologic type was
infiltrating ductal carcinoma (77%-89.8%) in the
Middle East J Cancer 2018; 9(3): 243-251248
Table 5. Analysis of data pooled from 2224 cases at the Cancer
Research Center (CRC).
Pathology Percent
DCIS 4.0
IDC 79.3
1IDC+DCIS 1
ILC 9.1
MIXED IDC+ILC 2.9
IDC+Paget 0.4
Paget 0.3
Other 0.4
DCIS: Ductal carcinoma in situ IDC: Invasive ductal Carcinoma ILC:
Invasive lobular Carcinoma
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Iranian studies27,32,37 and 85.2% according to a
study in Pakistan.34
The clinical stages of the tumor according to
studies from 1985-2005 showed improvement;
the tumors have been down-staged according to
tumor size and number of positive lymph nodes.16
A ten year study (1985-1995) reported early stage
cancers consist of 30% of cancers which improved
to 64%-75% after 2006.9,27,32,37
A 2013 study from Saudi Arabia reported that
40% of cases had advanced stage with breast
masses that measured >10 cm in 58% of females.
A study published in 2017 from India reported
45.7% of patients were advanced stage.14 In
Pakistan, 60.7% of cases had stage 2 disease.34 A
study from Northeast Iran that included 797
patients reported that 48.4% had early breast
cancer and 51.6% had advanced breast cancer.
This finding was similar to the CRC results with
54.5% early breast cancer and 45.5% advanced
cancer.10,11
According to the frequency of advanced stage
disease in different Iranian studies (30%-36%), it
seems that health system notification for increasing
the early detection program should be improved.
Because of the key role of biomarkers such as
steroid receptors, C-erb (HER2) in correct
management of this disease, the importance of
further investigations and standard evaluation of
biomarkers should focus on different regions of
Iran.
There was no significant relation between
tumor size and biologic markers in the studies.
Only PR negativity had a relationship to more
positive lymph nodes. Positive P53 was associated
with increased metastasis in one study without any
relation with steroid receptors. In that study,
overall survival and DFS significantly differed in
P53 positive and P53 negative metastatic patient
groups.28,29
Two studies in 2005 and 2009 showed no
relationship between biomarkers and tumor
recurrence.26,28 However a recently published
study showed negative biomarkers (ER-, PR-,
HER2-) had a poorer prognosis in the 4 subtypes.
ER- HER2+ had shorter survival compared to
ER+HER2- cases.32
Akbari et al. reported that in the absence of ER
and LVI, the probability of tumor recurrence
increased. Other receptors had no association
with recurrence. Therefore, negative ER status
along with other proliferative indexes could
increase the risk of recurrence.30 A recently
published CRC study showed that high grade and
stage, younger age, negative ER status, LVI and
LN positive were the most common risk factors
for recurrence.31
In a research by Akbari et al. the possibility of
death in patients with visceral recurrence
(P=0.001, HR=8.04) was greater than locoregional
and bone recurrence (P=0.031, HR=4.42) and
also more than local recurrence.31
According to the standardized mortality ratio
(SMR), the five-year mortality was 6.74, for the
10-year period was 6.55, and 1.26 for the 15-
year period. Total mortality amongst Iranian
women of all ages was 0.13%-1.9%. The 15-year
SMR was similar in breast cancer patients and the
normal population.8 The data obtained from
mortality rate recorded in Pakistan showed that
36% of total deaths were for breast cancer
patients.34 Turkey had a mortality rate of 11.9
per 100,000,13 whereas the mortality rate in India
was 12.7 per 100,000.14
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Table 6. Clinical Staging for breast cancer in Iran according to 5 published articles and the CRC data pool (1985-2013).
Stage 1985-1995 1996-2000 2001-2005 2006-2011 2007-2013
N=903(%) N=778(%) N=1265 N=1250 N=1812
0 9(1%) 2(0.4%) 43(6.6%) 17(1.36%) 10(0.6%)
1 18(2%) 21(3.8%) 53(8.2%) 194(15.52%) 234(12.8%)
2 244(21%) 392(71.1%) 326(50.2%) 634(50.74%) 1034(57.1%)
3 632(69.9%) 136(24.7%) 220(35%) 309(24.72%) 511(28.8%)
4 - - - 54(4.34%) 23(1.26%)
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Conclusion
Breast cancer is the most prevalent cancer in
Iranian females, therefore, a critical investigation
into its epidemiology is necessary. Our study has
attempted to compare different Iranian studies,
neighboring countries, and the world in terms of
breast cancer mortality, prevalence, staging,
recurrence and survival. The differences in
findings from Iranian studies and other countries
indicate the multi-dimensional aspect of this
cancer and necessitates multi-center involvement
by governmental authorities, clinicians, and
scientists.
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